Resource Library
S-DUAL™: A novel bispecific antibody scaffold with higher heterodimer formation
Here we report the development of S-DUAL™ , Samsung Biologics’ BsAb Platform with a novel asymmetrical structure that delivers a 99% HC-LC-pairing success rate. The platform’s unique asymmetric design enables the seamless addition of complementarity-determining regions (CDRs) of interest without additional engineering processes, while maintaining high binding affinity and productivity.
Here we report the development of S-DUAL™ , Samsung Biologics’ BsAb Platform with a novel asymmetrical structure that delivers a 99% HC-LC-pairing success rate. The platform’s unique asymmetric design enables the seamless addition of complementarity-determining regions (CDRs) of interest without additional engineering processes, while maintaining high binding affinity and productivity.